This review examines the role of testosterone replacement therapy (TRT) in weight loss and body composition improvement in men with testosterone deficiency, particularly those who are overweight or obese. The study shows that TRT leads to significant reductions in fat mass, waist circumference, and BMI, while increasing lean body mass.
This review examines the benefits and misconceptions surrounding testosterone deficiency (hypogonadism) and testosterone replacement therapy (TRT). It highlights the significant health risks associated with testosterone deficiency, such as sexual dysfunction, bone loss, and metabolic syndrome, and argues that TRT can provide substantial benefits, including improved sexual function, overall well-being, and
This article examines the relationship between testosterone levels, testosterone replacement therapy (TRT), and cardiovascular (CV) health. It highlights that low testosterone is associated with increased risks of diabetes, metabolic syndrome, inflammation, and dyslipidemia and may independently predict higher cardiovascular and all-cause mortality. The review discusses potential benefits of TRT in
Testosterone therapy was found to significantly reduce insulin resistance in men with metabolic syndrome (MetS) and hypogonadism, particularly in those not receiving antiglycaemic therapy. The study, a randomized controlled trial, included 184 men, with 113 receiving testosterone undecanoate (TU) and 71 receiving placebo. Results showed a significant reduction in HOMA-IR,
This meta-analysis examined the effects of hormone replacement therapy (HRT) on components of metabolic syndrome in postmenopausal women. Results showed that HRT significantly reduced abdominal fat, insulin resistance, and new-onset diabetes, while improving cardiovascular health by reducing cholesterol ratios, blood pressure, and inflammatory markers. Oral HRT was more effective than
This review discusses the negative impact of testosterone deficiency (TD) and 5α-reductase inhibitors (such as finasteride) on metabolic and sexual health in men. TD leads to increased fat mass, insulin resistance, metabolic syndrome, erectile dysfunction, and decreased quality of life. The use of 5α-reductase inhibitors, which block the conversion of
The study explores how menopause and postmenopausal hormone therapy (PHT) influence the risk of metabolic syndrome in women. It discusses potential benefits of PHT in reducing risks related to glucose metabolism, lipid profiles, and cardiovascular health. The findings suggest a role for individualized postmenopausal care, particularly considering metabolic risks.
Testosterone therapy (TTh) is an effective treatment for men with testosterone deficiency (TD), improving sexual function, bone density, metabolic health, and overall quality of life. It normalizes testosterone levels, enhancing energy, libido, and metabolic control. While generally safe, cardiovascular risks should be monitored. Various delivery methods, such as injections and
This study evaluated the cardiovascular safety of testosterone replacement therapy in men aged 45-80 with hypogonadism and cardiovascular risk. It found that testosterone therapy did not increase cardiovascular risk, showing noninferiority to the placebo. This research supports the safety of testosterone for long-term use in men with metabolic concerns and
This review explores the impact of menopause on metabolic dysfunction and the role of menopausal hormone therapy (MHT) in mitigating components of metabolic syndrome (MetS), including visceral obesity, dyslipidemia, type 2 diabetes (T2D), and hypertension (HTN). MHT has been shown to improve body composition, lipid profiles, insulin sensitivity, and blood
